Key result
Novel oral anticoagulants carry a clinically significant risk for gastrointestinal bleeding, and their management in acute and elective settings differs from that used with warfarin.
Why the study?
What is the risk of gastrointestinal bleeding with novel oral anticoagulants and how should it be managed compared to warfarin?
Population
Patients at risk of thromboembolism taking novel oral anticoagulants
Comparison
Novel oral anticoagulants vs Warfarin
Design
Review
Authors
Loading...
NOAC GI bleeding may require tailored protocols distinct from warfarin; leaves open need for randomized validation of management strategies.
What is the risk of gastrointestinal bleeding with novel oral anticoagulants and how should it be managed compared to warfarin?
This review highlights the significant risk of gastrointestinal bleeding associated with NOACs and outlines specific management strategies, emphasizing the differences in reversal between direct thrombin inhibitors and factor Xa inhibitors.
Abraham et al. (2013) conducted a review in Thromboembolism and NOAC-related gastrointestinal bleeding. Novel oral anticoagulants (NOACs) vs. Warfarin was evaluated. Novel oral anticoagulants carry a clinically significant risk for gastrointestinal bleeding, and their management in acute and elective settings differs from that used with warfarin.